Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
6.66
+0.16 (2.46%)
Oct 29, 2024, 4:00 PM EDT - Market closed

Company Description

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.

Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.

In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.

It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.

Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals logo
Country United Kingdom
Founded 2000
Industry Biotechnology
Sector Healthcare
Employees 21
CEO Stephen Stamp

Contact Details

Address:
1 Caspian Point, Caspian Way
Cardiff, CF10 4DQ
United Kingdom
Phone 44 29 2048 0180
Website biodexapharma.com

Stock Details

Ticker Symbol BDRX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency GBP
CIK Code 0001643918
ISIN Number US59564R7089
SIC Code 2834

Key Executives

Name Position
Stephen A. Stamp Chief Executive Officer, Chief Financial Officer, Company Secretary and Director
Dr. Daniel Palmer MBA, Ph.D. Vice President of Technology
Nicola Tuckwell Vice President and Head of Clinical Operations
Steve Ellul Chief Business Officer
Fiona Sharp Group Financial Controller

Latest SEC Filings

Date Type Title
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 16, 2024 424B3 Prospectus
Oct 15, 2024 6-K Report of foreign issuer
Oct 4, 2024 6-K Report of foreign issuer
Sep 27, 2024 424B3 Prospectus